Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30418000 | 1.00 | PARP1 (0.72) | PARP1PARP2 | |
| SCHEMBL1052345 | 0.94 | PARP1 (0.66) | PARP1PARP2 | |
| SCHEMBL1083535 | 0.93 | PARP1 (0.65) | PARP1PARP2 | |
| SCHEMBL1047444 | 0.89 | PARP1 (0.63) | PARP1PARP2 | |
| SCHEMBL1047286 | 0.84 | PARP1 (0.74) | PARP1PARP2 | |
| SCHEMBL1048855 | 0.84 | PARP1 (0.71) | PARP1PARP2 | |
| SCHEMBL631189 | 0.84 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL630129 | 0.78 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL10321364 | 0.78 | PARP1 (0.71) | PARP1PARP2 | |
| SCHEMBL1052052 | 0.78 | PARP1 (0.67) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | claimed |
| US-8513433-B2 | Small molecule inhibitors of PARP activity | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | claimed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | claimed |
| WO-2011002520-A2 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2011-01-06 | — | — | WO | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3769087-B1 | A METHOD FOR DIAGNOSING METABOLIC DISORDER | UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-11747342-B2 | Proteomic biomarkers of sepsis in young patients | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230266328-A1 | MULTIOMIC ANALYSIS OF NANOPARTICLE-CORONAS | THE UNIVERSITY OF MANCHESTER (GB) | 2023-08-24 | — | — | US | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230083288-A1 | PROBE AND METHOD FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230028696-A1 | Predictive Markers of Psychosis | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2023-01-26 | — | — | US | disclosed |
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | disclosed |
| US-8513433-B2 | Small molecule inhibitors of PARP activity | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130137595-A1 | BIOMARKERS FOR LYMPHOMA | BATTELLE MEMORIAL INSTITUTE (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2553458-A2 | SERUM AND TISSUE BIOMARKERS OF HUMAN HCC | Modpro AB (SE) | 2013-02-06 | — | — | EP | disclosed |
| US-20120183973-A1 | BIOMARKER COMPOSITION FOR DETECTING DIABETIC RETINOPATHY AND DIAGNOSTIC KIT THEREFOR | SNU R & DB FOUNDATION (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011150994-A2 | SERUM AND TISSUE BIOMARKERS OF HUMAN HCC | BORLAK JUERGEN (DE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011002520-A2 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | PARP1 92/4885PARP2 108/4885 |
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | PARP1 1/4885PARP2 4/4885 |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | PARP1 1/4885PARP2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.